• Molecular NameBuclizine
  • SynonymBuclizina [INN-Spanish]; Buclizine Dihydrochloride; Buclizine Hydrochloride; Buclizinum [INN-Latin]; Histabutyzine Dihydrochloride; Vibazine Hydrochloride
  • Weight433.039
  • Drugbank_IDDB00354
  • ACS_NO82-95-1
  • Show 3D model
  • LogP (experiment)7.749
  • LogP (predicted, AB/LogP v2.0)6.41
  • pkaN/A
  • LogD (pH=7, predicted)6.38
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.95
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds6
  • TPSA6.48
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antihistamine of the piperazine derivative family.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed following oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A